New Video: Private Equity is Improving Treatments for Blood Clot Patients
Featuring Anthos Therapeutics in Boston, MA
WASHINGTON, D.C. — Today, the American Investment Council released the third video in a series highlighting how private equity is investing in innovative technologies and devices that benefit patients and improve lives. This video features Anthos Therapeutics, a Massachusetts-based biopharmaceutical company conducting late-stage clinical trials on an exciting new drug that has the potential to prevent blood clots.
Blood clots, which lead to strokes and heart attacks, are responsible for 1 in 4 deaths in the United States. Backed by Blackstone Life Sciences, Anthos Therapeutics is pioneering a new treatment that could save millions of lives.
“Without the backing of private equity, this kind of drug at this stage of development would sit on the shelf and wouldn’t be possible.” – John Glasspool, CEO of Anthos Therapeutics.
“We needed private equity behind us to get this program started.” confirmed Dan Bloomfield, M.D., Chief Medical Officer at Anthos Therapeutics.
“Private equity, to me, means innovation and investment in the future of medicine.” – Alex Yi, Senior Medical Director at Anthos Therapeutics.
Massachusetts is home to 621 private equity backed businesses, which support 307,000 jobs across the state. 164 of those businesses supporting 93,437 jobs are in Boston alone.
Learn more about how private equity is investing in medical technologies that improve lives by watching the other videos in this series, featuring Headlands Research and Helix.
